Bevacizumab for newly diagnosed ovarian cancers: Best candidates among high-risk disease patients (icon-7)

Olivier Colomban, Michel Tod, Julien Peron, Timothy J. Perren, Alexandra Leary, Adrian D. Cook, Christophe Sajous, Gilles Freyer, Benoit You

    Résultats de recherche: Contribution à un journalArticleRevue par des pairs

    21 Citations (Scopus)

    Résumé

    Bevacizumab is approved as a maintenance treatment in first-line setting in advanced-stage III-IV ovarian cancers, because GOG-0218 and ICON-7 phase III trials demonstrated progression-free survival benefits. However, only the subgroup of patients with high-risk diseases (stage IV, and incompletely resected stage III) derived an overall survival (OS) gain in the ICON-7 trial (4.8 months). The modeled CA-125 elimination rate constant K (KELIM) parameter, based on the longitudinal CA- 125 kinetics during the first 100 days of chemotherapy, is a potential indicator of the tumor primary chemo-sensitivity. In the ICON-7 trial dataset, the OS of patients within the low- and high-risk disease groups was assessed according to treatment arms and KELIM. Among the patients with high-risk diseases, those with favorable standardized KELIM of at least 1.0 (n=214, 46.7%) had no survival benefit from bevacizumab, whereas those with unfavorable KELIM less than 1.0 (n=244, 53.2%) derived the highest OS benefit (absolute difference = 9.1 months, 2-sided log-rank P=.10; Cox hazard ratio = 0.78, 95% confidence interval = 0.58 to 1.04, 2-sided P=.09).

    langue originaleAnglais
    Numéro d'articlepkaa026
    journalJNCI Cancer Spectrum
    Volume4
    Numéro de publication3
    Les DOIs
    étatPublié - 1 janv. 2021

    Contient cette citation